CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 44 enrolled
Drug / intervention
Stereotactic Body Radiationradiation
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00832780
NCT00832780N/ACompleted
CompareCT.gov

INST 0810: Phase II Study of Stereotactic Body Radiation Therapy Using Tomotherapy for Tumors of the Lung

New Mexico Cancer Research Alliance·interventional·Posted Jan 30, 2009·Updated May 21, 2021

In Brief

A clinical study evaluating Stereotactic Body Radiation for Lung Cancer and 2 related conditions. Completed, enrolled 44 participants across 1 site.

Detailed Summary

The purpose of this study is to determine the response of lung tumors to radiation therapy. This study will be using a type of radiation therapy called tomotherapy. Tomotherapy is a relatively new kind of therapy which is able to focus a large amount of radiation to a small area with relatively less radiation to the surrounding non-cancerous part of the organ. This study is being done to find out if this technique is able to control the cancer better or not than the standard radiation and also to study its safety.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Cancer, Non Small Cell Lung Cancer, Solid Tumors
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 30, 2009
Enrollment StartJan 1, 2008
Primary CompletionDec 1, 2015
Study CompletionDec 1, 2018
TodayJul 2, 2026
Enrollment to primary: 7.9 yearsPosted 17.4 years ago

Interventions

Stereotactic Body Radiationradiation

A total of 60 Gy using 12 Gy per fraction over 5 fractions to be given within 10 calendar days. Each fraction of 12 Gy will be divided into 2 fractions of 6 Gy given in one day within 6 hours. Dose will be prescribed to the isodose line which covers at least 90% of the planning target volume. Dose homogeneity +/- 5%.